Sign inCreate account

Report workspace tools

NCT02329561COMPLETEDanonymous

Comparative, Randomized, Double-Blind, Single-Dose, 2-way Crossover Study to Evaluate the Pharmacokinetics and Analgesic Effect of Labopharm Tramadol Contramid® OAD 200 mg Tablets or Placebo in Healthy Young and Elderly Adult Volunteers

Sponsor

Source record

Université de Montréal

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

Tramadol and O-desmethyltramadol enantiomers

Indication / condition

AI-normalized

Aging

Intervention

Source record

Tramadol extended release 200 mg, CP/T, Placebo

Source & freshness

Source record

NCT ID

NCT02329561

Original source

ClinicalTrials.gov

Source last updated

Dec 31, 2014

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT02329561

Title

Comparative, Randomized, Double-Blind, Single-Dose, 2-way Crossover Study to Evaluate the Pharmacokinetics and Analgesic Effect of Labopharm Tramadol Contramid® OAD 200 mg Tablets or Placebo in Healthy Young and Elderly Adult Volunteers

Sponsor

Université de Montréal

Status

COMPLETED

Phase

PHASE1

Condition raw

Aging

Condition normalized

Aging

Modality raw

Aging

Modality normalized

small molecule

Target raw

Tramadol and O-desmethyltramadol enantiomers

Target normalized

Tramadol and O-desmethyltramadol enantiomers

Interventions

Tramadol extended release 200 mg, CP/T, Placebo

Public preview

Source record

This completed clinical trial evaluated the pharmacokinetics and pharmacodynamics of tramadol and its active metabolite, O-desmethyltramadol, in healthy young and elderly adults. The study aimed to understand age-related differences in drug metabolism and analgesic effects, which could inform dosing and safety profiles for geriatric patients.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Comparative, Randomized, Double-Blind, Single-Dose, 2-way Crossover Study to Evaluate the Pharmacokinetics and Analgesic Effect of Labopharm Tramadol Contramid® OAD 200 mg Tablets or Placebo in Healthy Young and Elderly Adult Volunteers

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT02329561

Status

COMPLETED

Phase

PHASE1

Sponsor

Université de Montréal

Executive brief

Investment-Ready Snapshot

This completed clinical trial evaluated the pharmacokinetics and pharmacodynamics of tramadol and its active metabolite, O-desmethyltramadol, in healthy young and elderly adults. The study aimed to understand age-related differences in drug metabolism and analgesic effects, which could inform dosing and safety profiles for geriatric patients.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedDec 31, 2014
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02329561

Indication

Aging

Modality

small molecule

Target

Tramadol and O-desmethyltramadol enantiomers

Intervention

Tramadol extended release 200 mg, CP/T, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.